Invesco DB G10 Currency ... Stock Quote DBV - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

25.41

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

38.115M

Previous Close

25.41

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

1,500,000

Dividend Yield

PE Ratio

314.87

Earnings Per Share (EPS)

0.08

Revenue

569k

Net Profit

121k

The investment seeks to track changes, whether positive or negative, in the level of the DBIQ Optimum Yield Diversified Commodity Index Excess Return. The fund pursues its investment objective by investing in index commodities. The index commodities are Light Sweet Crude Oil (WTI), Heating Oil, RBOB... The investment seeks to track changes, whether positive or negative, in the level of the DBIQ Optimum Yield Diversified Commodity Index Excess Return. The fund pursues its investment objective by investing in index commodities. The index commodities are Light Sweet Crude Oil (WTI), Heating Oil, RBOB Gasoline, Natural Gas, Brent Crude, Gold, Silver, Aluminum, Zinc, Copper Grade A, Corn, Wheat, Soybeans, and Sugar. The index is composed of notional amounts of each of these commodities. Show more

Sector

Commodity Brokers & Dealers

Industry

Commodity Brokers & Dealers

Website

dbfunds.db.com

Headquarters

Downers Grove, Illinois, USA

Founded

DBV Technologies, BioNet-Asia & Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT f...

DSMB expressed no safety concerns with Viaskin rPT 25 µg Following positive DSMB review, dosing with Viaskin rPT 50 µg has been initiated DBV Technologies (Euronext: DBV – ISIN:...

DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced the presentation of two posters on its Viaskin Peanut development program at the American...

DBV Technologies to Attend Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced that members of its management team will present and host investor meetings at the...

DBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic Patients

Most advanced product candidate for the treatment of IgE-mediated cow’s milk allergy in development today FDA Fast Track designation for Viaskin Milk was granted in September 2016 DBV...

DBV Technologies Reports September 30, 2016 Cash Position

DBV Technologies, (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), today announced its cash and cash equivalents as of September 30, 2016. Cash and cash equivalents...

DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Jo...

The study, CoFAR6, evaluated peanut-allergic patients 4 to 25 years of age Primary endpoint of the study was met; greatest benefit observed in children DBV Technologies (Euronext:...

Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut

Favorable safety and high compliance were reported in OLFUS, consistent with prior results A vast majority of children continue to respond to treatment and tolerate larger doses of...

DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow’s Milk Protein Allergy

DBV first to announce Fast Track designation for IgE-mediated CMPA; Viaskin Milk is currently being investigated in a Phase IIb study Second Fast Track designation for the Viaskin...

DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Chil...

BAGNEUX, France, April 9, 2015 (GLOBE NEWSWIRE) -- DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Children DBV...

DBV Technologies Reports Full Year 2014 Financial Results

BAGNEUX, France, March 25, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DBGIDigital Brands Group Inc	$ 0.2761 (72.78%)	4.27M
GRTSGritstone bio Inc	$ 0.0659 (22.04%)	7.61M
DRUGBright Minds Biosciences Inc	$ 3.01 (20.88%)	8.36M
ATIFATIF Holdings Ltd	$ 1.1995 (19.95%)	6.22k
ONCTOncternal Therapeutics Inc	$ 1.20 (14.29%)	8.81k
VRPXVirpax Pharmaceuticals Inc	$ 0.422 (-11.34%)	3.74k
HRYUHanryu Holdings Inc	$ 0.18 (-9.68%)	68.32k
XPONExpion360 Inc	$ 3.20 (-9.09%)	115.35k
DRCTDirect Digital Holdings Inc	$ 3.36 (-6.93%)	3.98k
SGDSafe and Green Development Corporation	$ 3.72 (-6.53%)	31.44k
DRUGBright Minds Biosciences Inc	$ 3.01 (20.88%)	8.36M
GRTSGritstone bio Inc	$ 0.0659 (22.04%)	7.61M
INVOINVO BioScience Inc	$ 1.34 (8.06%)	5.62M
DBGIDigital Brands Group Inc	$ 0.2761 (72.78%)	4.27M
INDVIndivior PLC	$ 7.90 (0.00%)	2.84M